Ranibizumab for choroidal neovascularization secondary to pseudoxanthoma elasticum: 4-year results from the PIXEL study in France

PURPOSE: To evaluate the long-term effectiveness and safety of ranibizumab 0.5 mg in patients with choroidal neovascularization (CNV) secondary to pseudoxanthoma elasticum (PXE) in a real-world setting. METHODS: A descriptive, observational, multicenter study in a retrospective and prospective cohor...

Descripción completa

Detalles Bibliográficos
Autores principales: Mimoun, Gérard, Ebran, Jean-Marc, Grenet, Typhaine, Donati, Alain, Cohen, Salomon-Yves, Ponthieux, Anne
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Berlin Heidelberg 2017
Materias:
Medical Ophthalmology
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541092/
https://www.ncbi.nlm.nih.gov/pubmed/28493086
http://dx.doi.org/10.1007/s00417-017-3685-y

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5541092/
https://www.ncbi.nlm.nih.gov/pubmed/28493086
http://dx.doi.org/10.1007/s00417-017-3685-y

Ejemplares similares